This is actually pretty interesting. Generic drug manufacturing has relatively high barriers to entry, but relatively low margins because there's no way for brands to command a premium. Standardized insurance costs work to prevent price discovery, and consequently you end up with supply shocks, especially for drugs that are difficult to store.

Even given dictatorial power over the FDA I'm still not sure exactly what I would do to untangle the swirl of incentive problems here.